Pulmonary arterial hypertension (PAH) can lead to severe, life-threatening conditions such as heart failure and premature death. Specific therapies can manage PAH temporarily, but their long-term benefits are unclear. Patients who have an inadequate response or are refractory to conventional medical treatments are considered for double lung or heart-lung transplants; however, the waitlist counters this process. A lung allocation score reduces the waiting time and ensures that organs go to those in most need.
For more insights on the indications, contraindications, and management of PAH, join Dr. Basha Khan and Dr. Prashant Bobhate for an exclusive session on “ Transplant and Pulmonary Hypertension ” on 17 th August, 3:00 PM IST onwards. Session highlights: Pulmonary hypertension management Indication and evaluation of lung transplant Lung or heart transplant— The better…
